Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

14.2K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
14.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

287
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
287

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation.

Lupus·2013
Same author

Autoantibodies against CD74 in spondyloarthritis.

Annals of the rheumatic diseases·2013
Same author

Immunoadsorption for systemic lupus erythematosus.

Atherosclerosis. Supplements·2010
Same author

Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.

Atherosclerosis. Supplements·2010
Same author

Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus.

Annals of the rheumatic diseases·2008
Same author

IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Annals of the rheumatic diseases·2005

Related Experiment Video

Updated: May 7, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 8, 2009

29.6K

Immunoadsorption (IAS) for systemic lupus erythematosus.

G H Stummvoll

    Lupus
    |February 10, 2011
    PubMed
    Summary

    Immunoadsorption (IAS) offers rapid removal of pathogenic factors for severe systemic lupus erythematosus (SLE) patients. While experimental and costly, IAS is a vital rescue therapy for life-threatening conditions due to its fast action and safety.

    Area of Science:

    • Immunology
    • Nephrology
    • Extracorporeal Therapies

    Background:

    • Immunoadsorption (IAS) serves as a rescue therapy for severe systemic lupus erythematosus (SLE) patients unresponsive to standard treatments.
    • This extracorporeal technique efficiently removes pathogenic immunocomplexes (ICs) and autoantibodies (Abs).

    Discussion:

    • IAS demonstrates short- to mid-term efficacy and biocompatibility in SLE, particularly for renal involvement.
    • Despite lacking randomized controlled trial (RCT) evidence, IAS is employed in critical situations.
    • The procedure is considered experimental and relatively expensive.

    Key Insights:

    • IAS provides rapid removal of disease-causing molecules in severe SLE.
    • The therapy has an acceptable safety profile for critically ill patients.

    More Related Videos

    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
    12:04

    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

    Published on: November 1, 2015

    17.7K
    Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
    10:16

    Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies

    Published on: September 15, 2016

    12.4K

    Related Experiment Videos

    Last Updated: May 7, 2026

    Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
    12:19

    Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

    Published on: October 8, 2009

    29.6K
    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
    12:04

    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

    Published on: November 1, 2015

    17.7K
    Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
    10:16

    Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies

    Published on: September 15, 2016

    12.4K
  • Efficacy and biocompatibility are supported by existing data, though RCT evidence is pending.

    • Outlook:

    • Further research, including RCTs, is needed to solidify the role of IAS in SLE management.
    • Exploring cost-effectiveness and wider accessibility of IAS could enhance its clinical utility.
    • IAS may become a more established treatment option for refractory SLE cases with more robust evidence.